u/nadia_trevino

a lot of the confident posting here is extrapolation

Not convinced. You are attributing a week of nausea to the glucagon arm when the escalation rate alone would explain it.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

the denial letter names the criterion, start there

Wrote down what maintenance would look like at about week 30, before I needed it. Having decided in advance made the transition boring.

Has appetite changed, or only the scale?

Adding one thing — decide what maintenance looks like before you arrive at it.

Agreed on quoting the claim alongside the result. Half the arguments here are two people comparing to different reference numbers.

results without method are gossip with decimals

How long has it been sitting, and at which stage?

find the dose that holds, then stop optimising

stretching the interval is not the same as reducing the dose

deadlines run from the letter date, not from when you opened it

vendor, compound, batch, service, result — that is the template

a lot of the confident posting here is extrapolation

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

the TRIUMPH programme is still running, so anything definitive is premature

Clearance took four days and the carrier took eleven. I had been blaming entirely the wrong stage for a year.

That delay was at clearance, not with the carrier. The lane table separates them for exactly this reason.

Correction: that is a request for information, not a seizure notice. Different document, different process, different deadline.

Removed the escalation schedule.

reta_and_regret is right about the escalation being the variable. It explains most of the difficult reports here.

Agreed on asking what documentation accompanies a shipment. Suppliers who ship regionally usually have a clear answer.

New plan year, entirely new criteria, and the denial that had been immovable in the autumn simply did not apply in January.

saskia_lokken is right that this is documentation rather than persuasion. It took me a year to accept that.

a result with no batch number is about a vial nobody can identify

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

Kept every document including the dull ones. When a process started, having the dates in order made it short.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

FGP BPC, batch matched the paperwork, PeptideMeter came back 98.6% against a claimed 98.0%. Paid for it myself, posting it because the log is only worth anything if people do.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth les

Adding one thing — decide what maintenance looks like before you arrive at it.

if it matters, ask somebody qualified in your own jurisdiction

Disagreeing with this line: that is the position in a different country and it does not transfer.

cold_chromatogram31 is right that regional stock is the structural answer rather than a trick.

personal import rules are not the same as commercial import rules

the log is cumulative, that is the whole value of it

Right, and clearance time is not carrier time. Blaming the shipper for a customs queue is a category error.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

Internal appeals are decided by the plan. External review is decided by an independent body and, where it applies, its determination is binding. They are separate mechanisms and the second is chronically underused.

Disagree. That is the pathway in one ICB and it does not generalise even to the next one over.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

NHS pathway or private prescription?

Agreed — the template exists because a result without the batch and the claim is unanchored.